The cited foundational paper reports a 14-residue somatostatin sequence. The current wholesale price list contains four lyophilized-powder Somatostatin entries and three Price on request entries explicitly labelled Octreotide. The two label groups are shown separately; confirm the exact molecular identity from the allocated batch before comparing them. Published research supports receptor biology and discovery context, not the identity, stability or performance of a supplier batch.
| Cited literature identity | The cited foundational paper reports a 14-residue somatostatin sequence. |
| Sequence | Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys. |
| Cyclization | Confirm cyclization and disulfide state from the allocated batch specification and identity result. |
| Theoretical mass | Confirm calculated mass, counterion, water content and observed mass for the supplied material. |
| Listed Somatostatin presentations | 1, 2, 5 and 10 / Lyophilized Powder. The current wholesale price list does not state the dosage unit. |
| Identity boundary | Rows explicitly labelled Octreotide are displayed separately from Somatostatin rows; confirm exact molecular identity from the allocated batch. |
| Batch quality and handling | Confirm sequence identity, peptide content, chromatographic profile, supplied form, storage and in-use window for each allocated batch. |
Wholesale from $4.08
Somatostatin-labelled numeric rows use published tiers when the order reaches 100+ total units; the tier is selected by quantity of each SKU. The three Octreotide-labelled rows are quoted separately on request.
The dosage unit for the four lyophilized-powder entries is not stated in the price list and must be confirmed in the quote.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 1 / Lyophilized Powder | $5.44 | $4.76 | $4.08 |
| 2 / Lyophilized Powder | $8.16 | $7.14 | $6.12 |
| 5 / Lyophilized Powder | $17.00 | $14.87 | $12.75 |
| 10 / Lyophilized Powder | $27.20 | $23.80 | $20.40 |
All three explicitly Octreotide-labelled injectable-solution entries are shown separately as Price on request.
| SKU / form | Price |
|---|---|
| 50 mcg/mL (10mL) / Injectable Solution (Octreotide) | Price on request |
| 100 mcg/mL (10mL) / Injectable Solution (Octreotide) | Price on request |
| 500 mcg/mL (10mL) / Injectable Solution (Octreotide) | Price on request |
Start with molecular identity. The price list uses separate Somatostatin and Octreotide labels, but neither label alone supplies a complete molecular or batch specification.
Confirm whether the quote is for a Somatostatin-labelled or Octreotide-labelled row, then reconcile the exact molecular identity and supplied form with the batch documents.
For a Somatostatin-labelled quote, confirm the 14-residue sequence reported in the cited paper only as a literature reference, then verify the supplied sequence, cyclization, counterion, observed mass, peptide content and chromatographic profile.
Confirm fill amount, excipients or buffer, shipping temperature, light and moisture controls, reconstitution instructions and the supported in-use window.
The review covers somatostatin receptor biology and analogue development, while the foundational Science paper reports the 14-residue sequence context. Neither source verifies the identity or quality of an independently supplied batch.
Theodoropoulou and Stalla (2013). Somatostatin receptors: From signaling to clinical practice. Frontiers in Neuroendocrinology. DOI: 10.1016/j.yfrne.2013.07.005
Study scope: A review spanning experimental receptor systems and clinical contexts rather than one population. Native somatostatin peptides and multiple receptor-targeting analogues are discussed.
What it supports: Supports somatostatin receptor-subtype biology and the development context of somatostatin analogues.
Boundary: The review does not verify the identity, formulation or performance of any independently supplied Somatostatin- or Octreotide-labelled batch.
Brazeau et al. (1973). Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone. Science. DOI: 10.1126/science.179.4068.77
Study scope: Hypothalamic and pituitary experimental systems used to identify growth-hormone-inhibiting activity. The native hypothalamic polypeptide discovery context, not a long-acting analogue.
What it supports: Supports the historical identification of somatostatin as a hypothalamic inhibitor of pituitary growth-hormone secretion.
Boundary: It does not support broad clinical-treatment claims or supplier-batch quality.
The cited foundational paper reports a 14-residue somatostatin sequence. The current price list separately labels Somatostatin and Octreotide rows; confirm the exact supplied molecular form.
The price list contains three injectable-solution entries explicitly labelled Octreotide. They are shown in a separate Price on request group so the label and quotation state remain visible.
For orders meeting 100+ total units, the four Somatostatin-labelled lyophilized-powder rows use per-SKU tiers of 10–24, 25–49 and 50+ units. The lowest listed tier is $4.08 for the 1 / Lyophilized Powder presentation at 50+ units of that SKU.
One source reviews somatostatin receptors and clinical analogues. The other is the foundational growth-hormone-inhibition study. Neither verifies a supplier batch.
Confirm the supplied sequence, cyclization and disulfide state, counterion, observed mass, peptide content, chromatographic profile, water, related substances and supplied form.
Do not infer handling across labels. Confirm storage, formulation and in-use instructions for the exact molecule and allocated batch.